Leading Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715) today announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of US firm Concert Pharmaceuticals (Nasdaq: CNCE), with the news pushing the latter’s shares up more than 20% to $8.30.
The acquisition will be through a tender offer for an upfront payment of $8.00 per share (a 33% premium to Concert’s 30-day average) in cash, or $576 million in equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share of common stock in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods, subject to the terms and conditions contained in a contingent value rights agreement detailing the terms of the CVRs.
The transaction was approved by the boards of directors of both companies, and is expected to be completed in the first quarter of 2023. This marks Sun Pharma; biggest deal since buying generic drugmaker Ranbaxy Laboratories for $3.2 billion in 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze